RESEARCH TRIANGLE PARK, N.C., March 16, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in oncology, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the 22nd Annual Future Leaders in the Biotech Industry conference on Friday, March 20, at 3:50 p.m. EDT at the Millennium Broadway Hotel & Conference Center in New York City.
For more information about the conference, please visit: http://www.biocentury.com/conferences/futureleaders/dates.
About G1 Therapeutics, Inc.
G1 Therapeutics, Inc. is a privately held clinical-stage pharmaceutical company based in Research Triangle Park, NC that focuses on the discovery and development of novel small-molecule therapies to address significant unmet needs in oncology. The company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of first-in-class compounds and best-in-class drug candidates that address two markets: CDK4/6 antineoplastics and protection of the bone marrow from damage by chemotherapy (chemoprotection). The company's lead program, G1T28, is a highly potent and selective CDK4/6 inhibitor that is currently being evaluated in Phase 1a clinical trials.
Visit www.g1therapeutics.com for more information.